The global Viral Vector and Vaccine market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Viral Vector and Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Viral Vector and Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Viral Vector and Vaccine include ABL, Addgene, Aldevron, Boehringer Ingelheim International GmbH, Brammer Bio, Charles River Laboratories, Creative-Biogene, Fujifilm Corporation and General Electric, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Viral Vector and Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vector and Vaccine.
The Viral Vector and Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Viral Vector and Vaccine market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vector and Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
ABL
Addgene
Aldevron
Boehringer Ingelheim International GmbH
Brammer Bio
Charles River Laboratories
Creative-Biogene
Fujifilm Corporation
General Electric
MerckKGaA
Novasep
Pfizer
Spark Therapeutics
Thermo Fisher Scientific
Waisman Biomanufacturing
Segment by Type
Adenovirus
Fowlpox Virus
Attenuated Yellow Fever
Vaccinia Virus Vectors
Segment by Application
Research Institutes
Biopharmaceutical Companies
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Viral Vector and Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Viral Vector and Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Viral Vector and Vaccine 麻豆原创 Overview
1.1 Product Overview and Scope of Viral Vector and Vaccine
1.2 Viral Vector and Vaccine Segment by Type
1.2.1 Global Viral Vector and Vaccine 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 Adenovirus
1.2.3 Fowlpox Virus
1.2.4 Attenuated Yellow Fever
1.2.5 Vaccinia Virus Vectors
1.3 Viral Vector and Vaccine Segment by Application
1.3.1 Global Viral Vector and Vaccine 麻豆原创 Value by Application: (2023-2029)
1.3.2 Research Institutes
1.3.3 Biopharmaceutical Companies
1.3.4 Others
1.4 Global Viral Vector and Vaccine 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Viral Vector and Vaccine Revenue 2018-2029
1.4.2 Global Viral Vector and Vaccine Sales 2018-2029
1.4.3 Global Viral Vector and Vaccine 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Viral Vector and Vaccine 麻豆原创 Competition by Manufacturers
2.1 Global Viral Vector and Vaccine Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Viral Vector and Vaccine Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Viral Vector and Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Viral Vector and Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Viral Vector and Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Viral Vector and Vaccine, Product Type & Application
2.7 Viral Vector and Vaccine 麻豆原创 Competitive Situation and Trends
2.7.1 Viral Vector and Vaccine 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Viral Vector and Vaccine Players 麻豆原创 Share by Revenue
2.7.3 Global Viral Vector and Vaccine 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Viral Vector and Vaccine Retrospective 麻豆原创 Scenario by Region
3.1 Global Viral Vector and Vaccine 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Viral Vector and Vaccine Global Viral Vector and Vaccine Sales by Region: 2018-2029
3.2.1 Global Viral Vector and Vaccine Sales by Region: 2018-2023
3.2.2 Global Viral Vector and Vaccine Sales by Region: 2024-2029
3.3 Global Viral Vector and Vaccine Global Viral Vector and Vaccine Revenue by Region: 2018-2029
3.3.1 Global Viral Vector and Vaccine Revenue by Region: 2018-2023
3.3.2 Global Viral Vector and Vaccine Revenue by Region: 2024-2029
3.4 North America Viral Vector and Vaccine 麻豆原创 Facts & Figures by Country
3.4.1 North America Viral Vector and Vaccine 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Viral Vector and Vaccine Sales by Country (2018-2029)
3.4.3 North America Viral Vector and Vaccine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Viral Vector and Vaccine 麻豆原创 Facts & Figures by Country
3.5.1 Europe Viral Vector and Vaccine 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Viral Vector and Vaccine Sales by Country (2018-2029)
3.5.3 Europe Viral Vector and Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Viral Vector and Vaccine 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Viral Vector and Vaccine 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Viral Vector and Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Viral Vector and Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Viral Vector and Vaccine 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Viral Vector and Vaccine 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Viral Vector and Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Viral Vector and Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Viral Vector and Vaccine 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Viral Vector and Vaccine 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Viral Vector and Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Viral Vector and Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Viral Vector and Vaccine Sales by Type (2018-2029)
4.1.1 Global Viral Vector and Vaccine Sales by Type (2018-2023)
4.1.2 Global Viral Vector and Vaccine Sales by Type (2024-2029)
4.1.3 Global Viral Vector and Vaccine Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Viral Vector and Vaccine Revenue by Type (2018-2029)
4.2.1 Global Viral Vector and Vaccine Revenue by Type (2018-2023)
4.2.2 Global Viral Vector and Vaccine Revenue by Type (2024-2029)
4.2.3 Global Viral Vector and Vaccine Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Viral Vector and Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Viral Vector and Vaccine Sales by Application (2018-2029)
5.1.1 Global Viral Vector and Vaccine Sales by Application (2018-2023)
5.1.2 Global Viral Vector and Vaccine Sales by Application (2024-2029)
5.1.3 Global Viral Vector and Vaccine Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Viral Vector and Vaccine Revenue by Application (2018-2029)
5.2.1 Global Viral Vector and Vaccine Revenue by Application (2018-2023)
5.2.2 Global Viral Vector and Vaccine Revenue by Application (2024-2029)
5.2.3 Global Viral Vector and Vaccine Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Viral Vector and Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 ABL
6.1.1 ABL Corporation Information
6.1.2 ABL Description and Business Overview
6.1.3 ABL Viral Vector and Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 ABL Viral Vector and Vaccine Product Portfolio
6.1.5 ABL Recent Developments/Updates
6.2 Addgene
6.2.1 Addgene Corporation Information
6.2.2 Addgene Description and Business Overview
6.2.3 Addgene Viral Vector and Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Addgene Viral Vector and Vaccine Product Portfolio
6.2.5 Addgene Recent Developments/Updates
6.3 Aldevron
6.3.1 Aldevron Corporation Information
6.3.2 Aldevron Description and Business Overview
6.3.3 Aldevron Viral Vector and Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Aldevron Viral Vector and Vaccine Product Portfolio
6.3.5 Aldevron Recent Developments/Updates
6.4 Boehringer Ingelheim International GmbH
6.4.1 Boehringer Ingelheim International GmbH Corporation Information
6.4.2 Boehringer Ingelheim International GmbH Description and Business Overview
6.4.3 Boehringer Ingelheim International GmbH Viral Vector and Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Boehringer Ingelheim International GmbH Viral Vector and Vaccine Product Portfolio
6.4.5 Boehringer Ingelheim International GmbH Recent Developments/Updates
6.5 Brammer Bio
6.5.1 Brammer Bio Corporation Information
6.5.2 Brammer Bio Description and Business Overview
6.5.3 Brammer Bio Viral Vector and Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Brammer Bio Viral Vector and Vaccine Product Portfolio
6.5.5 Brammer Bio Recent Developments/Updates
6.6 Charles River Laboratories
6.6.1 Charles River Laboratories Corporation Information
6.6.2 Charles River Laboratories Description and Business Overview
6.6.3 Charles River Laboratories Viral Vector and Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Charles River Laboratories Viral Vector and Vaccine Product Portfolio
6.6.5 Charles River Laboratories Recent Developments/Updates
6.7 Creative-Biogene
6.6.1 Creative-Biogene Corporation Information
6.6.2 Creative-Biogene Description and Business Overview
6.6.3 Creative-Biogene Viral Vector and Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Creative-Biogene Viral Vector and Vaccine Product Portfolio
6.7.5 Creative-Biogene Recent Developments/Updates
6.8 Fujifilm Corporation
6.8.1 Fujifilm Corporation Corporation Information
6.8.2 Fujifilm Corporation Description and Business Overview
6.8.3 Fujifilm Corporation Viral Vector and Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Fujifilm Corporation Viral Vector and Vaccine Product Portfolio
6.8.5 Fujifilm Corporation Recent Developments/Updates
6.9 General Electric
6.9.1 General Electric Corporation Information
6.9.2 General Electric Description and Business Overview
6.9.3 General Electric Viral Vector and Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.9.4 General Electric Viral Vector and Vaccine Product Portfolio
6.9.5 General Electric Recent Developments/Updates
6.10 MerckKGaA
6.10.1 MerckKGaA Corporation Information
6.10.2 MerckKGaA Description and Business Overview
6.10.3 MerckKGaA Viral Vector and Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.10.4 MerckKGaA Viral Vector and Vaccine Product Portfolio
6.10.5 MerckKGaA Recent Developments/Updates
6.11 Novasep
6.11.1 Novasep Corporation Information
6.11.2 Novasep Viral Vector and Vaccine Description and Business Overview
6.11.3 Novasep Viral Vector and Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Novasep Viral Vector and Vaccine Product Portfolio
6.11.5 Novasep Recent Developments/Updates
6.12 Pfizer
6.12.1 Pfizer Corporation Information
6.12.2 Pfizer Viral Vector and Vaccine Description and Business Overview
6.12.3 Pfizer Viral Vector and Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Pfizer Viral Vector and Vaccine Product Portfolio
6.12.5 Pfizer Recent Developments/Updates
6.13 Spark Therapeutics
6.13.1 Spark Therapeutics Corporation Information
6.13.2 Spark Therapeutics Viral Vector and Vaccine Description and Business Overview
6.13.3 Spark Therapeutics Viral Vector and Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Spark Therapeutics Viral Vector and Vaccine Product Portfolio
6.13.5 Spark Therapeutics Recent Developments/Updates
6.14 Thermo Fisher Scientific
6.14.1 Thermo Fisher Scientific Corporation Information
6.14.2 Thermo Fisher Scientific Viral Vector and Vaccine Description and Business Overview
6.14.3 Thermo Fisher Scientific Viral Vector and Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Thermo Fisher Scientific Viral Vector and Vaccine Product Portfolio
6.14.5 Thermo Fisher Scientific Recent Developments/Updates
6.15 Waisman Biomanufacturing
6.15.1 Waisman Biomanufacturing Corporation Information
6.15.2 Waisman Biomanufacturing Viral Vector and Vaccine Description and Business Overview
6.15.3 Waisman Biomanufacturing Viral Vector and Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Waisman Biomanufacturing Viral Vector and Vaccine Product Portfolio
6.15.5 Waisman Biomanufacturing Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Viral Vector and Vaccine Industry Chain Analysis
7.2 Viral Vector and Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Viral Vector and Vaccine Production Mode & Process
7.4 Viral Vector and Vaccine Sales and 麻豆原创ing
7.4.1 Viral Vector and Vaccine Sales Channels
7.4.2 Viral Vector and Vaccine Distributors
7.5 Viral Vector and Vaccine Customers
8 Viral Vector and Vaccine 麻豆原创 Dynamics
8.1 Viral Vector and Vaccine Industry Trends
8.2 Viral Vector and Vaccine 麻豆原创 Drivers
8.3 Viral Vector and Vaccine 麻豆原创 Challenges
8.4 Viral Vector and Vaccine 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
ABL
Addgene
Aldevron
Boehringer Ingelheim International GmbH
Brammer Bio
Charles River Laboratories
Creative-Biogene
Fujifilm Corporation
General Electric
MerckKGaA
Novasep
Pfizer
Spark Therapeutics
Thermo Fisher Scientific
Waisman Biomanufacturing
听
听
*If Applicable.
